1.Inhibitory effect of mutant cytosine deaminase D314A against human colon cancer cells
Maocai SUN ; Yiming HUANG ; Zhengcai ZHU ; Jianping WANG ; Lizong SHEN ; Wenxi WU
Chinese Journal of Cancer Biotherapy 2009;16(6):595-599
Objective:To construct a mutant D314A of Escherichia coli cytosine deaminase (EC-CD, substitution of an alanine (A) for the aspartic acid (D) at position 314 of cytosine deaminase) and investigate its antitumor effect. Methods: Eukaryotic expression plasmid containing EC-CD gene (pcDNA3.1-CD~(wt)) was constructed, and the mutant pcDNA3.1-CD~(D314A) plasmid, with aspartic acid (D) at position 314 of EC-CD gene substituted by alanine (A) (EC-CD~(D314A)), was established by site-directed mutation. EC-CD~(wt) and EC-CD~(D314A) were transfected into human colon cancer cell line LoVo via Lipofectamine~(tm) 2000, and positive LoVo-CD~(wt) and LoVo-CD~(D314A) cells stably expressing corresponding genes were selected by G418. The cytotoxicity and bystander effects of EC-CD and EC-CD~(D314A) genes on LoVo cells were e-valuated by MTT assay. Results: The mutant D314A was confirmed by sequence analysis. EC-CD and EC-CD~(D314A) mRNA were expressed after transfected into LoVo cells. The IC_(50) of Lovo-CD~(D314A) cells was (85.13±0.60) mmol/L, which was significantly lower than that of LoVo-CD~(wt) cells ([689.76±0.45] μmol/L, P=0.000). Bystander effect assay showed that, when at the ratio of 30%, the survival rates of LoVo-CD~(wt) cells and Lovo-CD~(D314A) cells were (48.5±0.49)% and (17.3±0.40) % (P = 0.000), respectively. Conclusion: Mutatant EC-CD gene (EC-CD~(D314A)) has a significantly in-creased antitumor effect on LoVo cells compared with wild type EG-CD gene, and it may become a new candidate gene for tumor gene therapy.
2.Biological healing mechanism of magnetic porous Ca3 (PO4) 2: an experimental study
Zhaohui LOU ; Xianjie DONG ; Anmin CHEN ; Zhengcai XIA ; Shuzhen SUN ; Tao CHENG
Chinese Journal of Trauma 2011;27(7):659-662
Objective To study the causes and theoretical basis for good bone healing ability of magnetic Porous Ca3 (PO4) 2 ( MPTCP). Methods Seven MPTCP specimens with size of 2 cm × 1 cm × 0.5 cm were placed in the material physical system for detecting 42 times and the mean detection value was used to measure the MPTCP curve. The attachment 16451B of impedance spectrometer HP RLC was employed to measure dielectric spectroscopy and dielectric spectroscopy of MPTCP. Four-wire method was used to measure the impedance of MPTCP. Results The magnetic intensity changed rapidly when magnetic field was in a range of-10,000-10,000 Oe. The peak of dielectric spectroscopy and impedance of magnetic bioceramics was in the range of 103-104 Hz. When the external electromagnetic wave of frequency was ≤ 1 000 Hz, electrical impedance of MPTCP was large;while when the electromagnetic wave frequency was≥1 000 Hz, the impedance was relatively small and stable. Conclusion The environmental magnetic fields may change the magnetic and electric behavior of MPTCP and promote the biological healing, which may be the cause for the good bone healing ability of MPTCP.
3. Mechanism of promoted neovascularization by SVF after fat grafting
Zhengcai WANG ; Jingjing MA ; Zichun GU ; Wenjia SUN ; Li CHEN ; Hua LI
Chinese Journal of Plastic Surgery 2019;35(8):814-818
Stromal vascular fraction(SVF)are the remaining cells after removing mature fat cells in the adipose tissue. Containing a certain amount of adipose derived stem cells(ADSCs), SVF also includes many other cells, which may have the potential of promoting angiogenesis. In this review, the role of SVF in angiogenesis after fat transplantation was summarized by intensive reading relative literature in recent years. The result is that angiogenesis and fat graft revascularization are regulated by various factors: SVF promotes secretion of a diverse array of cytokines and growth which are capable of stabilizing endothelium vascular network. ADSCs have the potential of differentiating into smooth muscle cells and endothelial cells which can coroperate to form new blood vessels.
4.Application of strengthening propaganda and education for ischemic stroke patient′s spouse
Jianjun LAI ; Zuhuang ZHANG ; Zhengcai SUN ; Zhenxiang LI
Chinese Journal of Modern Nursing 2015;21(3):259-264
Objective To discuss the application of strengthening propaganda and education for ischemic stroke patient′s spouse.Methods Ischemic stroke patients′spouse ( n =100 ) were divided into experimental group ( strengthening propaganda and education ) and control group ( normal propaganda and education) on average by randomly controlled trail.SS-QQL, SF-36, SDS and SAS had been used for assessment of ischemic stroke patients and their spouse′s quality of life, anxiety and depression.Results The scores of SDS for patients and spouses were (51.24 ±6.65) and (49.01 ±7.32) in the experimental group comparing with (58.21 ±6.31) and (56.51 ±7.12) in the control group at reexamination after 12 months discharged (t=5.474, 5.288;P<0.05);similarly, the scores of SAS were (50.24 ±7.24) and (47.01 ± 7.51) lower than (56.21 ±7.35) and (55.51 ±7.42) in the control group (t=4.166, 5.796; P<0.05). the scores of dimensions SS-QQL and spouses′quality of life were higher than those in the control group ( P<0.05) except dimensions of physical pain (P>0.05).Conclusions Strengthening propaganda and education during hospitalization can minimize patient′s anxiety, depression and enhance them and their spouses′quality of life.
5.Notoginsenoside Ft1 acts as a TGR5 agonist but FXR antagonist to alleviate high fat diet-induced obesity and insulin resistance in mice.
Lili DING ; Qiaoling YANG ; Eryun ZHANG ; Yangmeng WANG ; Siming SUN ; Yingbo YANG ; Tong TIAN ; Zhengcai JU ; Linshan JIANG ; Xunjiang WANG ; Zhengtao WANG ; Wendong HUANG ; Li YANG
Acta Pharmaceutica Sinica B 2021;11(6):1541-1554
Obesity and its associated complications are highly related to a current public health crisis around the world. A growing body of evidence has indicated that G-protein coupled bile acid (BA) receptor TGR5 (also known as Gpbar-1) is a potential drug target to treat obesity and associated metabolic disorders. We have identified notoginsenoside Ft1 (Ft1) from